SGS acquires Keystone Bioanalytical to boost North American pharma testing
What's the deal? SGSDealroom has a profile for this one. Try Dealroom →, the Swiss testing and certification giant, has acquired Keystone BioanalyticalDealroom has a profile for this one. Try Dealroom →, a specialist in bioanalytical testing services. The deal is aimed at strengthening SGS's end-to-end drug development lifecycle testing capabilities for pharmaceutical and biotech companies in North America.
Keystone Bioanalytical brings expertise in bioanalytical testing — a critical step in drug development that measures how drugs behave in the body. By folding Keystone into its operations, SGS expands its service offering to pharma and biotech clients across the continent.
Why now? The North American pharma and biotech sectors are growing rapidly, with companies increasingly outsourcing specialised testing to third-party providers. Demand for bioanalytical services has surged as drug pipelines expand, particularly in biologics and cell and gene therapies that require complex analytical work.
SGS has been on an acquisition spree in recent years, building out its health sciences division to capture more of the drug development value chain. Adding Keystone fills a gap in its North American footprint.
What could go wrong? Integration is always the risk with acquisitions. Merging laboratory operations, quality systems, and company cultures can slow things down — especially in a highly regulated industry where compliance missteps carry serious consequences.
There's also competitive pressure. Contract research organisations like Charles River Laboratories, Eurofins, and WuXi AppTec are all vying for the same pharma outsourcing dollars.
The signal: SGS, classified as a mature company on Dealroom, is absorbing Keystone Bioanalytical while the latter is still in its early growth stage — a pattern increasingly common as large testing and certification firms snap up nimble specialists to plug capability gaps. The move puts SGS in more direct competition with fellow mature players such as Charles River Laboratories in a pharma outsourcing market where scale and end-to-end coverage are fast becoming table stakes.
Read more: prnewswire.com
